Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients - Wikidata - awgldk - TriplyDB

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

http://www.wikidata.org/entity/Q24598792

about

Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens Relevance of tumor-infiltrating lymphocytes in breast cancer Acquired and intrinsic resistance in cancer immunotherapy Pathways and therapeutic targets in melanoma Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.The use of immunotherapy in the treatment of melanoma Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.Adoptive cell transfer as personalized immunotherapy for human cancer.Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients.Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma Relationships between tumor microenvironment and clinicopathological parameters in meningioma SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.Genotyping of cutaneous melanoma.A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response Reprogramming antitumor immunity Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.Broadening the repertoire of melanoma-associated T-cell epitopes.Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties.Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity.Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.Update on use of aldesleukin for treatment of high-risk metastatic melanoma.Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy Adoptive T-cell therapy for cancer: boutique therapy or treatment modality?Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma.Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8 T Cells.Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.Exploiting the curative potential of adoptive T-cell therapy for cancer.Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.Immunotherapy for the management of advanced melanoma: the next steps.The use of endogenous T cells for adoptive transfer.

P2860

Q26745444-4A38A77D-BB83-47AF-82A4-88C4ECC67F02 Q26774669-BEC65A2E-50ED-4C50-B460-6EF072143F14 Q26795598-0BD1D8E3-E7E3-409C-8536-E92CCDF8C623 Q26827701-26938D67-EE11-4E67-B9E7-276AFF352906 Q26865736-32815304-1EFE-4C14-98B1-42A3EE732D67 Q27334215-0A7CFEAB-3980-4A39-A276-9530113ED231 Q28068378-6BC342AA-EF11-4032-B1EB-391313D44476 Q28085397-F5659E69-D477-429B-A486-3CD18A82373D Q30573747-F1E146F5-4F28-4C1C-8C38-3BBA6D6F0E6D Q33593858-064CA07C-D3AF-45BB-B71E-3AA62714C627 Q33839273-E584453B-7692-49B5-96A5-A9EDB2E34AAA Q34043643-DF4357CE-9547-47DA-916B-5269433BF17B Q34259974-F91CCBBD-6AA0-4701-B43D-CA1656273EAE Q34350259-2EFB6D1C-1F4C-4690-BE29-0458068BC6C1 Q34501928-DF17BDBA-88A9-42F6-B25D-9DB7A1531581 Q34558043-112B3E35-0CDA-4D85-84E7-93ED24644F36 Q34656292-3CAC0B0A-48E8-41D1-B38E-CA898CA44D79 Q34667738-05BA0CEC-9565-4DA6-AEC5-25271AEF04E5 Q35182795-B712FF5E-F8E2-4947-8A02-A2F52C8478F7 Q35216812-A21DAD7C-A59A-4F63-9130-F4431D073C11 Q35507358-2F324028-A84B-475A-81FD-25A4CF3A114B Q35546276-B314A06C-F04A-40C1-A9AE-6CB0506BD36A Q36027584-E98A33A4-6192-444D-A5AE-80C0B58D604D Q36060241-89DDFEB0-8288-4459-8D84-809234A99116 Q36316627-2457FDFF-5425-4D34-AEB0-0BFBF512539A Q36553576-123C8B89-27E0-45D6-801F-55DD8EB4A96C Q36710982-0480882B-3C39-415B-9292-1AE2198E8AAC Q36711007-D5E44005-69DE-4D52-B86E-452C7DA11785 Q37031696-F18D9460-19C8-47A5-A575-630E16E188D0 Q37065838-39E99E60-B5C5-43BB-ACE0-484700C9BB3B Q37107516-A151A2A4-CAF1-41F3-8399-C482988BFB3F Q37316580-C6F5DDB2-F9B8-431F-AD3E-07DDA63CABA7 Q37320131-9965CFB0-95F7-460E-9505-ABE77C30ED81 Q37402534-8D9B9B2C-CDE2-419F-A1DF-1D2A8BEA478B Q37561102-4177FE90-919D-432A-BA1F-62554F048AFF Q37576033-30380252-C3BD-4D02-97EC-2C5389AA36C7 Q37590119-EDA14062-932F-407D-8741-593E70F73230 Q37718529-2AA833E5-94A0-437F-9CDA-590B06544CF9 Q38091675-1E3052BB-FE4F-4519-92E4-31425B17C0A4 Q38170503-5B292A47-3257-4688-B841-034DAA87F953

P2860

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

http://www.wikidata.org/entity/Q24598792

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Specific lymphocyte subsets pr ...... n metastatic melanoma patients

@ast

Specific lymphocyte subsets pr ...... n metastatic melanoma patients

@en

Specific lymphocyte subsets pr ...... n metastatic melanoma patients

@nl

type

label

Specific lymphocyte subsets pr ...... n metastatic melanoma patients

@ast

Specific lymphocyte subsets pr ...... n metastatic melanoma patients

@en

Specific lymphocyte subsets pr ...... n metastatic melanoma patients

@nl

prefLabel

Specific lymphocyte subsets pr ...... n metastatic melanoma patients

@ast

Specific lymphocyte subsets pr ...... n metastatic melanoma patients

@en

Specific lymphocyte subsets pr ...... n metastatic melanoma patients

@nl

P1433

Q24598792-FD9EBCE5-A3D8-41A8-91E0-45DADC594C8B

P1476

Q24598792-48A10772-2130-44DD-8830-E9AC122E8D17

P2093

Q24598792-02AF183F-DF08-4B5D-B64A-85BA33C88093

Q24598792-03F614A4-D7F6-4C61-BEDB-1E7C11915081

Q24598792-0654D3B2-C4C8-417A-8C61-EEC40F732849

Q24598792-0ED65714-43BF-46A8-BE28-718C8ACBB264

Q24598792-122F5074-398E-4635-81E1-104364CFE786

Q24598792-1A96313E-94E7-4D50-96FE-99A792A4DED8

Q24598792-306CFDF2-0948-4325-AB12-D21548932B84

Q24598792-3211DE8D-457E-4994-B8F7-8320A812B7F3

Q24598792-39B9FEF4-7632-491B-AE64-77CA4635C048

Q24598792-3D55C49E-3595-442E-96E2-5116580CEA2B

P2860

Q24598792-003746F7-D758-4A72-8695-64E036BA36AE

Q24598792-05716A44-62CC-4A6D-BF5C-7C8D1A266288

Q24598792-06FEA660-AB65-48C9-A957-D05C3DF90D1E

Q24598792-09CA82A9-D32B-4EA1-AA21-63999E0D53C1

Q24598792-153CA9BD-3E6A-4742-9FC8-EEF77007E96B

Q24598792-15F414EC-9CA6-4BBB-BF77-37AF326B6B45

Q24598792-1611D399-1EF0-47B3-B669-3926A8D82E29

Q24598792-2349078C-D89F-4F51-A0A9-6318833A0D75

Q24598792-27893104-A801-40A5-9514-B7667617B20C

Q24598792-4F124AAD-D9AD-4129-BFE9-94AD71FC3B68

P304

Q24598792-3E27FED8-9B77-4D43-9AD3-EDDBB6A2DCC9

P31

Q24598792-AE433108-527D-4BE5-9589-75F09A0ACF16

P3181

Q24598792-F6C37981-751E-4ED4-89EC-B219A3000B4C

P356

Q24598792-B23C0CB7-9DD2-4C5E-A4E8-AF7F4C85BF23

P407

Q24598792-B6C9E4BE-A0E6-4D05-A0AE-5F3A192AF333

P433

Q24598792-FF296A90-EDAD-4CF0-9E8C-CC4FC473C8C0

P478

Q24598792-49D5F75C-8190-4B2A-804B-FCBC81AE69BB

P577

Q24598792-0DB7BF1C-4B00-4CF2-821B-198A40A0907A

P698

Q24598792-9402FECE-AFFA-4697-B69B-822EF5D465C6

P921

Q24598792-7A36C669-26F5-4BA1-9498-DF3DC521A7D9

P932

Q24598792-E946AF34-5A7D-4D69-847E-6DB74314753F

P3181

P356

1078-0432.CCR-12-1177

P1433

Clinical Cancer Research

P1476

Specific lymphocyte subsets pr ...... n metastatic melanoma patients

@en

P2093

Agop Bedikian

http://www.w3.org/2001/XMLSchema#string

Anthony Lucci

http://www.w3.org/2001/XMLSchema#string

Audrey Gonzalez

http://www.w3.org/2001/XMLSchema#string

Chantale Bernatchez

http://www.w3.org/2001/XMLSchema#string

Christopher Toth

http://www.w3.org/2001/XMLSchema#string

Elizabeth Shpall

http://www.w3.org/2001/XMLSchema#string

Gladys Alvarado

http://www.w3.org/2001/XMLSchema#string

Gregory Lizee

http://www.w3.org/2001/XMLSchema#string

Jade Homsi

http://www.w3.org/2001/XMLSchema#string

Janice N Cormier

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Central memory and effector memory T cell subsets: function, generation, and maintenance

Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.

Temozolomide for the treatment of metastatic melanoma: a systematic review.

Putting the brakes on BTLA in T cell-mediated cancer immunotherapy

P304

6758-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3655425

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1078-0432.CCR-12-1177

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23032743

http://www.w3.org/2001/XMLSchema#string

P921

P932

3525747

http://www.w3.org/2001/XMLSchema#string